Autoantibodies
Neuronal autoantibodies associated with poorer neuropsychological and motor outcomes 6 months after stroke: results from the PHYS-STROKE trial
An exploratory PHYS-STROKE biomarker analysis links baseline neuronal autoantibodies to selected six-month outcomes, but only the NMDAR–subjective mobility association survives correction for multiple comparisons.